Bimatoprost
Who holds supplier records for Bimatoprost? 13 organisations hold a current record for Bimatoprost: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: Taiwan (3), India (2), Italy (2), United States (1) and 4 other countries (4); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Bimatoprost: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/bimatoprost
Reading the evidence
- 13 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Bimatoprost expires 8 Jun 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (13)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Bimatoprost. Country is the organisation's recorded country, not necessarily the manufacturing site.
- C-SQUARED PHARMA LTDUnited StatesActive DMF 25903 · latest filing Mar 2012
- CAYMAN PHARMA SROCzechia Company GMP cert on recordActive DMF 24353 · latest filing Jan 2011
- CHIROGATE INTERNATIONAL INCTaiwanActive DMF 21382 · latest filing Feb 2008
- EUROAPI HUNGARY LTDHungaryActive DMF 29560 · latest filing Jul 2015
- EVERLIGHT CHEMICAL INDUSTRIAL CORPTaiwanActive DMF 22080 · latest filing Oct 2008
- FDC LimitedIndia Company GMP cert on recordActive DMF 40350 · latest filing Aug 2024
- INDUSTRIALE CHIMICA SRLItaly Company GMP cert on recordActive DMF 23480 · latest filing Jan 2010
- KYOWA PHARMA CHEMICAL CO LTDJapan Company GMP cert on recordActive DMF 21681 · latest filing Jun 2008
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 27044 · latest filing May 2013
- NEWCHEM SPAItaly Company GMP cert on recordActive DMF 41890 · latest filing Jun 2025
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 27217 · latest filing Jun 2013
- YS LIFE SCIENCE CO LTDActive DMF 24906 · latest filing Apr 2011
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 43476 · latest filing Jan 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (2)
Organisations whose Type II DMFs for Bimatoprost are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- India · Inactive DMF 26877 · filed May 2013
- United Kingdom · Inactive DMF 20911 · filed Oct 2007
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (15 listed products contain Bimatoprost). The latest listed patent expires 8 Jun 2036. The latest listed exclusivity runs to 9 Sept 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Bimatoprost is a prostaglandin analog used to treat certain types of glaucoma and ocular hypertension by reducing intraocular pressure. It also has cosmetic uses for promoting eyelash growth in individuals with hypotrichosis or inadequate eyelashes.
Chemical identity
- IUPAC name
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
- Canonical SMILES
- CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
- InChIKey
- AQOKCDNYWBIDND-FTOWTWDKSA-N
- Synonyms
- Latisse API, agn-192024, agn192024, durysta, ganfort component bimatoprost, latisse, lumigan, prostamide, zolymbus
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Prostaglandin Analog
- Chemical structure
- Prostaglandins
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Bimatoprost?
13 organisations hold an active US FDA Type II Drug Master File or a CEP for Bimatoprost: C-SQUARED PHARMA LTD (United States), CAYMAN PHARMA SRO (Czechia), CHIROGATE INTERNATIONAL INC (Taiwan), EUROAPI HUNGARY LTD (Hungary), EVERLIGHT CHEMICAL INDUSTRIAL CORP (Taiwan), FDC Limited (India), INDUSTRIALE CHIMICA SRL (Italy) and KYOWA PHARMA CHEMICAL CO LTD (Japan), and 5 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Bimatoprost Drug Master Files are active?
C-SQUARED PHARMA LTD (DMF 25903), CAYMAN PHARMA SRO (DMF 24353), CHIROGATE INTERNATIONAL INC (DMF 21382), EUROAPI HUNGARY LTD (DMF 29560), EVERLIGHT CHEMICAL INDUSTRIAL CORP (DMF 22080), FDC Limited (DMF 40350), INDUSTRIALE CHIMICA SRL (DMF 23480) and KYOWA PHARMA CHEMICAL CO LTD (DMF 21681) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Bimatoprost records mean?
2 organisations have only inactive Type II DMFs for Bimatoprost. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Bimatoprost?
Yes. The latest patent listed for an approved US product containing Bimatoprost expires 8 Jun 2036, across 15 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Bimatoprost supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Bimatoprost?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.